A living WHO guideline on drugs for covid-19

@article{Lamontagne2020ALW,
  title={A living WHO guideline on drugs for covid-19},
  author={F. Lamontagne and T. Agoritsas and H. Macdonald and Y. Leo and J. Diaz and A. Agarwal and J. Appiah and Y. Arabi and L. Blumberg and C. Calfee and B. Cao and M. Cecconi and G. Cooke and J. Dunning and H. Geduld and Patrick O Gee and Hela Manai and D. S. Hui and Seema Kanda and L. Kawano-Dourado and Yae-Jean Kim and N. Kissoon and A. Kwizera and J. H. Laake and F. R. Machado and Nida Qadir and R. Sarin and Yinzhong Shen and Linan Zeng and R. Brignardello-Petersen and L. Lytvyn and R. Siemieniuk and D. Zeraatkar and J. Bartoszko and Long Ge and Brittany J. Maguire and B. Rochwerg and G. Guyatt and P. Vandvik},
  journal={BMJ},
  year={2020},
  volume={370}
}
  • F. Lamontagne, T. Agoritsas, +36 authors P. Vandvik
  • Published 2020
  • Medicine
  • BMJ
  • Abstract Clinical question What is the role of drug interventions in the treatment and prevention of covid-19? Recommendations The first version on this living guidance focuses on corticosteroids. It contains a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19. Corticosteroids are inexpensive and are on the World Health Organisation list… CONTINUE READING
    50 Citations
    Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)
    Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
    • Highly Influenced
    • PDF
    Predicting outcomes in COVID-19: From internal validation to improving care
    Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines
    • PDF

    References

    SHOWING 1-10 OF 36 REFERENCES
    A living systematic review protocol for COVID-19 clinical trial registrations
    • 15
    Remdesivir for the Treatment of Covid-19 — Final Report
    • 1,081
    • PDF
    Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
    • 1,379